Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CYCNNASDAQ:ORGSNASDAQ:PHIOOTCMKTS:TDLAF On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCYCNCyclerion Therapeutics$3.17-0.1%$2.95$1.27▼$9.47$10.11M1.671.28 million shs14,650 shsORGSOrgenesis$1.76+0.4%$2.15$0.87▼$10.80$8.43M0.548,982 shs4,154 shsPHIOPhio Pharmaceuticals$2.98+20.9%$1.88$0.97▼$9.79$14.26M0.992.42 million shs2.01 million shsTDLAFTBG Diagnostics$0.04-14.0%$0.04$0.01▼$0.13$2.38M-12.386,655 shs3,200 shsThe Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCYCNCyclerion Therapeutics+1.28%+11.23%+4.59%+13.21%+14.44%ORGSOrgenesis0.00%-10.26%-26.78%-57.32%+174,999,900.00%PHIOPhio Pharmaceuticals+17.14%+20.59%+43.02%+89.23%-62.04%TDLAFTBG Diagnostics0.00%0.00%0.00%0.00%0.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCYCNCyclerion Therapeutics1.4011 of 5 stars0.05.00.00.00.63.30.6ORGSOrgenesis1.8897 of 5 stars0.05.00.04.40.60.00.0PHIOPhio Pharmaceuticals3.1215 of 5 stars3.52.00.00.03.32.51.3TDLAFTBG DiagnosticsN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCYCNCyclerion Therapeutics 0.00N/AN/AN/AORGSOrgenesis 0.00N/AN/AN/APHIOPhio Pharmaceuticals 3.00Buy$14.00370.59% UpsideTDLAFTBG Diagnostics 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest TDLAF, CYCN, PHIO, and ORGS Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/5/2025PHIOPhio PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$14.004/8/2025PHIOPhio PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$4.00 ➝ $4.00(Data available from 6/6/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCYCNCyclerion Therapeutics$2.08M4.89N/AN/A$4.62 per share0.69ORGSOrgenesis$662K12.74N/AN/A($6.58) per share-0.27PHIOPhio PharmaceuticalsN/AN/AN/AN/A$18.57 per shareN/ATDLAFTBG Diagnostics$2.33M1.02N/AN/AN/A∞Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCYCNCyclerion Therapeutics-$5.26M-$1.16N/A∞N/AN/A-55.32%-48.35%8/5/2025 (Estimated)ORGSOrgenesis-$55.36MN/A0.00∞N/A-3,827.81%N/A-130.18%8/6/2025 (Estimated)PHIOPhio Pharmaceuticals-$10.83M-$10.92N/A0.79N/AN/A-134.57%-108.39%8/13/2025 (Estimated)TDLAFTBG Diagnostics$530KN/A0.00∞N/AN/AN/AN/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCYCNCyclerion TherapeuticsN/AN/AN/AN/AN/AORGSOrgenesisN/AN/AN/AN/AN/APHIOPhio PharmaceuticalsN/AN/AN/AN/AN/ATDLAFTBG DiagnosticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCYCNCyclerion TherapeuticsN/A5.075.07ORGSOrgenesisN/A0.070.07PHIOPhio PharmaceuticalsN/A6.386.38TDLAFTBG DiagnosticsN/AN/AN/ACompare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCYCNCyclerion Therapeutics75.62%ORGSOrgenesis22.56%PHIOPhio Pharmaceuticals57.31%TDLAFTBG DiagnosticsN/AInsider OwnershipCompanyInsider OwnershipCYCNCyclerion Therapeutics34.30%ORGSOrgenesis5.66%PHIOPhio Pharmaceuticals0.59%TDLAFTBG Diagnostics3.60%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCYCNCyclerion Therapeutics303.21 million1.73 millionNo DataORGSOrgenesis1504.80 million4.53 millionNo DataPHIOPhio Pharmaceuticals104.80 million6.85 millionNot OptionableTDLAFTBG DiagnosticsN/A55.29 millionN/ANot OptionableTDLAF, CYCN, PHIO, and ORGS HeadlinesRecent News About These CompaniesGrapevines: Napa Valley College launches Regional Transportation, Distribution & Logistic (TDL) training programJanuary 15, 2022 | napavalleyregister.comCurtiss-Wright Updates TDL Software Products in Advance of DoD’s Link 16 Cryptographic Modernization Capability MandateJanuary 8, 2022 | newswiretoday.comGlobal Tunable Diode Laser (TDL) Analyzers Market Growth 2021-2026January 7, 2022 | reportsnreports.comGlobal and United States Tunable Diode Laser (TDL) Gas Analyzers Market Insights, Forecast to 2027December 23, 2021 | reportsnreports.comTDL: Week 10 Thursday scores and highlightsNovember 5, 2021 | kplctv.comRaiders Podcast: TDL Ruggs reaction and mailbagNovember 4, 2021 | msn.comTDL: Week 8 Thursday scores and highlightsOctober 22, 2021 | kplctv.comRaiders podcast: TDL Week 6 review vs. The BroncosOctober 20, 2021 | msn.comTDL: Week 7 Thursday scores and highlightsOctober 15, 2021 | kplctv.comTDL: Week 6 Thursday scores and highlightsOctober 8, 2021 | kplctv.comTDL Thursday scores and highlightsSeptember 24, 2021 | kplctv.comTBG Diagnostics Ltd.August 20, 2021 | barrons.comTDL Two-A-Days high school football previews scheduleAugust 10, 2021 | kplctv.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTDLAF, CYCN, PHIO, and ORGS Company DescriptionsCyclerion Therapeutics NASDAQ:CYCN$3.17 0.00 (-0.09%) As of 03:57 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Cyclerion Therapeutics, Inc., a biopharmaceutical company, develops treatments for serious diseases. It is developing Olinciguat, an orally administered vascular soluble guanylate cyclase (sGC) stimulator, which is in Phase 2 clinical trial to out-license for cardiovascular diseases; and Praliciguat, a systemic sGC stimulator that is licensed to Akebia Therapeutics, Inc. for the treatment of rare kidney disease. The company was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.Orgenesis NASDAQ:ORGS$1.76 +0.01 (+0.40%) As of 02:39 PM EasternOrgenesis Inc., a biotech company, focuses on cell and gene therapies worldwide. It operates through two segments, Octomera and Therapies. The company develops a Point of Care (POCare) platform that includes a pipeline of licensed cell based POCare therapies that are processed and produced under closed and automated POCare technology systems across a collaborative POCare network consisting of research institutes and hospitals. Its therapies include autologous; cell-based immunotherapies; and therapeutics for metabolic diseases, anti-viral diseases, and tissue regeneration. The company also provides development services, including regulatory services, pre-clinical studies, intellectual property services, and GMP process translation, as well as support services; hospital services; cell process development services; and distributed cell processing services. The company was formerly known as Business Outsourcing Service, Inc. and changed its name to Orgenesis Inc. in August 2011. Orgenesis Inc. was incorporated in 2008 and is headquartered in Germantown, Maryland.Phio Pharmaceuticals NASDAQ:PHIO$2.98 +0.52 (+20.93%) As of 03:57 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Phio Pharmaceuticals Corp. engages in the development of immuno-oncology therapeutics in the United States. The company is developing PH-762, an INTASYL compound in Phase 1b dose-escalating clinical trials to reduce the expression of cell death protein 1 (PD-1), a protein that inhibits T cells' ability to kill cancer cells; and PH-762 treated double positive tumor infiltrating lymphocytes, which is in Phase 1 clinical trials to treat advanced melanoma and other advanced solid tumors. It is also developing PH-894, an INTASYL compound in IND enabling studies to silence BRD4, a protein that controls gene expression in both T cells and tumor cells, effecting the immune system and the tumor. The company was formerly known as RXi Pharmaceuticals Corporation and changed its name to Phio Pharmaceuticals Corp. in November 2018. Phio Pharmaceuticals Corp. was incorporated in 2011 and is based in Marlborough, Massachusetts.TBG Diagnostics OTCMKTS:TDLAF$0.04 -0.01 (-14.00%) As of 09/7/2021TBG Diagnostics Limited, a molecular diagnostics company, develops, manufactures, and markets molecular diagnostics kits, instruments, and services in Taiwan and China. It provides ExProbe HLA and HPA kits for human leukocyte antigen (HLA) and human platelet antigens (HPA) allele genotyping, which uses real time polymerase chain reaction (PCR) techniques with sequence specific primers and probes; Morgan SSP HLA kits for determining HLA alleles using PCR techniques with sequence specific primers; HLAssure SBT HLA Kits for transplantation donor selection; and AccuType SBT analysis software to analyze sequences from all ab1 based files. The company also offers Morgan SSPal HLA Typing Analysis Software, a gel result interpretation software; HLA typing services that offer low to high resolution using PCR fragment analysis (SSP) and DNA sequencing (SBT); QPCR Q6000, a six-channel real time PCR instrument; QzNGS NGS that provides high resolution HLA genotyping; and COVID-19 testing kits. It serves clinical labs, blood centers, and bone marrow registry labs. The company was formerly known as Progen Pharmaceuticals Limited and changed its name to TBG Diagnostics Limited in December 2015. TBG Diagnostics Limited was incorporated in 1989 is based in Greenslopes, Australia. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Broadcom Slides on Solid Earnings, AI Outlook Still Strong The Market’s Silent Warning: What Bonds and Gold Reveal MongoDB Affirms Outlook and Accelerates Stock Price Reversal Are NVIDIA's Ethernet Wins Signs of Hope or Horror for Arista? AT&T: Is This Telecom Giant a Buy or a Bye for Your Portfolio? Why Visa's Innovation Engine Keeps It a Top Portfolio Pick Is Meta Plotting a Stablecoin Comeback Years After Libra's Flop? NVIDIA Regains Top Spot; FOMO Is Why It Will Continue to Rise Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
